Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2019
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
EyExam is focused on providing an accessible, affordable solution for diagnosing and tracking eye diseases such as age-related macular degeneration and diabetic retinopathy. The companys AI-based solution analyzes optical coherence tomography (OCT) images within seconds and delivers a detailed diagnosis, including urgency of care, biomarkers, and recommended treatment.
Q&A
- What is EyExam's primary focus?
- EyExam focuses on providing an accessible and affordable AI-based solution for diagnosing and tracking eye diseases like age-related macular degeneration and diabetic retinopathy.
- What technology does EyExam utilize for diagnosis?
- EyExam's solution uses Artificial Intelligence to analyze optical coherence tomography (OCT) images within seconds, providing detailed diagnoses, urgency of care, biomarkers, and treatment recommendations.
- When was EyExam founded?
- EyExam was founded in July 2019.
- What is the current status of EyExam?
- EyExam is currently inactive and ceased to operate in June 2020.
- What is EyExam's primary sector classification?
- EyExam's primary sector is Health Tech & Life Sciences.
- Who is the founder of EyExam?
- The founder of EyExam is Tamar Levi Vineberg.
- What is EyExam's current funding stage?
- EyExam is in the Pre-Funding stage.
Team · 1
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical Diagnostics
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
diagnosticspatientsartificial-intelligencetreatmentsdigital-healthcareophthalmologybiomarkersrecommendationseye-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019-7 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Jun 2020 ceased to operate |